What is the recommended initial management and pharmacologic treatment for hypertension?

Initial Management and Pharmacologic Treatment for Hypertension

For most adults with hypertension, initiate combination therapy with two first-line antihypertensive agents—specifically an ACE inhibitor or ARB plus either a thiazide/thiazide-like diuretic or a calcium channel blocker—preferably as a single-pill combination, targeting blood pressure <130/80 mmHg. 1, 2

Blood Pressure Thresholds for Pharmacologic Treatment

• Start antihypertensive medication immediately for all adults with systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. 1
• For adults with BP 130-139/80-89 mmHg, initiate drug therapy if they have established cardiovascular disease or a 10-year atherosclerotic CVD risk ≥10%. 1, 3
• Confirm the diagnosis with home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) before finalizing treatment, though do not delay therapy in patients with severe hypertension. 2, 4

Blood Pressure Targets

• Target BP <130/80 mmHg for most adults under 65 years of age. 1, 5, 3
• For adults ≥65 years, target systolic BP <130 mmHg if well tolerated. 3
• Intensive BP control to 120-129 mmHg systolic reduces major cardiovascular events by 25% and all-cause mortality by 27% compared to standard targets of <140/90 mmHg in high-risk patients. 5

First-Line Medication Selection

• The four first-line antihypertensive drug classes are: thiazide or thiazide-like diuretics, ACE inhibitors, ARBs, and calcium channel blockers. 1, 6, 3
• Initiate combination therapy with two drugs for most patients, particularly those with BP ≥20/10 mmHg above target or Grade 2 hypertension (≥140/90 mmHg). 1, 2, 4
• Preferred initial combinations include: (1) ACE inhibitor or ARB + thiazide/thiazide-like diuretic, or (2) ACE inhibitor or ARB + calcium channel blocker. 1, 2
• Use single-pill combinations whenever possible to improve medication adherence. 1, 2

Specific Drug Recommendations

• Thiazide-like diuretics (chlorthalidone 12.5-25 mg daily or indapamide 1.25-2.5 mg daily) are preferred over hydrochlorothiazide due to longer duration of action and superior cardiovascular event reduction. 2, 3
• For Black patients, initial therapy should include a thiazide-type diuretic or calcium channel blocker, either in combination with each other or with an ACE inhibitor or ARB. 1
• ACE inhibitors and ARBs are preferred in patients with diabetes, chronic kidney disease, or structural cardiac abnormalities due to organ-protective effects. 5

Treatment Escalation Algorithm

• If BP remains ≥140/90 mmHg on dual therapy at optimal doses, escalate to triple therapy: ACE inhibitor or ARB + calcium channel blocker + thiazide/thiazide-like diuretic, preferably as a single-pill combination. 1, 2, 7
• If BP remains uncontrolled on triple therapy, add spironolactone 25-50 mg daily as the preferred fourth-line agent. 7, 8
• Alternative fourth-line agents include amiloride, doxazosin, eplerenone, or alpha-blockers if spironolactone is not tolerated. 7

Essential Lifestyle Modifications

• Restrict dietary sodium intake to <2 grams/day (approximately 5 grams salt/day), which provides the greatest BP reduction among lifestyle interventions. 2, 6, 3
• Increase dietary potassium to 3500-5000 mg/day unless contraindicated by chronic kidney disease or hyperkalemia. 7, 6
• Implement the DASH (Dietary Approaches to Stop Hypertension) diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy products. 6, 3
• Achieve and maintain healthy body weight with target BMI 20-25 kg/m². 2, 6
• Engage in regular aerobic exercise for at least 150 minutes per week. 5, 6, 3
• Moderate or eliminate alcohol consumption. 6, 3

Monitoring Parameters After Treatment Initiation

• Check serum potassium and creatinine 2-4 weeks after initiating ACE inhibitors, ARBs, or diuretics to detect hyperkalemia or acute kidney injury. 2, 7
• Reassess BP within 2-4 weeks after any medication adjustment, with the goal of achieving target BP within 3 months of initiating or modifying therapy. 2, 7
• Monitor for orthostatic hypotension, especially in older adults, by measuring BP in both sitting and standing positions. 2
• Confirm BP control with home BP monitoring (target <135/85 mmHg) or 24-hour ambulatory monitoring (target <130/80 mmHg). 2, 7

Critical Pitfalls to Avoid

• Never start with monotherapy in patients with Grade 2 hypertension (BP ≥140/90 mmHg), as combination therapy is required for adequate control. 2, 4
• Never combine two RAS blockers (ACE inhibitor + ARB), as this increases adverse events without additional cardiovascular benefit. 2, 7
• Do not use nondihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with heart failure with reduced ejection fraction due to negative inotropic effects. 5
• Do not delay pharmacologic treatment for prolonged lifestyle modification trials in patients with confirmed hypertension, especially those with BP ≥140/90 mmHg. 2
• Avoid therapeutic inertia—if BP remains above target, escalate therapy promptly rather than continuing ineffective regimens. 7

Special Populations

• In patients with chronic kidney disease (eGFR 30-59 mL/min/1.73 m²), ACE inhibitors or ARBs are preferred first-line agents due to renal protective effects. 5
• In patients with left ventricular hypertrophy or structural heart disease, target BP <130/80 mmHg using ACE inhibitors or ARBs combined with thiazide diuretics or calcium channel blockers. 5
• Beta-blockers should be reserved for compelling indications such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or atrial fibrillation requiring rate control—not as first-line therapy for uncomplicated hypertension. 2